- Poster presentation
- Open Access
- Published:
Anidulafungin for candidemia/invasive candidiasis in non-neutropenic ICU patients
Critical Care volume 15, Article number: P240 (2011)
Introduction
A recent study found anidulafungin (ANI) safe and effective for candidemia/invasive candidiasis (C/IC) in selected populations of ICU patients [1]. A post hoc analysis of this study was performed to evaluate the efficacy of ANI in the same populations, but in non-neutropenic C/IC patients only.
Methods
A prospective, open label, multinational, phase 3b study in adult ICU patients (APACHE II score <25) with ≥1 of the following: post-abdominal surgery; age ≥65 years; renal/hepatic insufficiency; solid organ transplant; neutropenia; and/or solid tumor. C/IC was confirmed from 96 hours before to 48 hours after the start of study treatment. Patients received i.v. ANI (200 mg on day 1, 100 mg/day thereafter) for ≥10 days, with optional oral azole step-down therapy, for a total treatment duration of 14 to 56 days. Primary efficacy endpoint was global response at end of all therapy (EOT) in the evaluable modified intent-to-treat (eMITT) population; that is, excluding patients with missing/unknown responses. For the present analysis, all patients with neutropenia were excluded.
Results
The total MITT population (that is, confirmed C/IC and ≥1 dose of ANI) included 170 patients, 157 (92.4%) of whom were non-neutropenic. In these patients at baseline, 69.4% had candidemia, mean APACHE II score was 16.3 (range 4 to 26) and mean SOFA score 7.4 (range 0 to 20). In non-neutropenic eMITT patients, global response at EOT was 71.1% (95% CI = 62.9, 78.4). At the end of i.v. therapy, 2 weeks post-EOT and 6 weeks post-EOT the global response was 72.4%, 61.2% and 52.0%, respectively. When missing/unknown responses were included and classed as failures, global success was 64.3% at EOT. The 90-day Kaplan-Meier survival estimate was 55.0% (95% CI = 47.2, 62.9). Among all non-neutropenic patients with ≥1 dose of ANI, treatment-related (due to ANI and/or azole) AEs and serious AEs occurred in 29/201 (14.4%) and 3/201 (1.5%) of patients, respectively. The most common treatment-related AE was erythema in four patients (2.0%). Other treatment-related AEs occurred in ≤1.5% of non-neutropenic patients.
Conclusions
ANI was effective and safe for the treatment of C/IC in selected populations of non-neutropenic ICU patients.
References
- 1.
Paiva JA, et al.: Anidulafungin (ANID) for treatment of candidemia/invasive candidiasis (C/IC) in selected intensive care unit (ICU) populations. Crit Care Med 2010,38(12 Suppl):297.
Author information
Affiliations
Corresponding author
Rights and permissions
This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Ruhnke, M., Paiva, J., Meersseman, W. et al. Anidulafungin for candidemia/invasive candidiasis in non-neutropenic ICU patients. Crit Care 15, P240 (2011). https://doi.org/10.1186/cc9660
Published:
Keywords
- Candidiasis
- Azole
- Global Response
- Anidulafungin
- Sofa Score
